The abstract is read at the publisher; the summary is JClub's.
Hypofractionated salvage radiotherapy (65 Gy/26 fractions) after radical prostatectomy did not improve 4-year biochemical progression-free survival versus conventional RT (66 Gy/33) in 316 intermediate- to high-risk patients.
- Why it matters: Clinicians need evidence on whether shorter-course salvage RT can match conventional biochemical control while maintaining acceptable toxicity and patient-reported quality of life.
- What they did: In a phase III randomized trial (2019–2021), intensity-modulated RT with daily image guidance was delivered to the prostate bed, with elective pelvic nodal irradiation at clinician discretion; the primary endpoint was bPFS.
- The result: After a median 52.6-month follow-up, 4-year bPFS was 80.1% (HYPO) vs 78.1% (CONV), with no significant differences in DMFS (91.7% vs 91.0%) or CSS (100% vs 100%); grade ≥2 GI toxicity was higher with HYPO (7.9% vs 0.7%) but resolved by last follow-up, and quality-of-life was comparable.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.